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In South Africa, depressive and anxiety disorders are 
common in the general population. According to the 
World Health Organization-led South African Stress 
and Health (SASH) study, the 12-month prevalence 
of depressive and anxiety disorders (combined) was 
12.6%,4 while the lifetime prevalence of these disor-
ders was 25.6%.5 Similarly, the SASH study found a 12-
month prevalence of 5.8% and a lifetime prevalence of 
13.4% for substance use disorders.4-5 
There is good evidence from international research 
that the prevalence of depression and anxiety in peo-
ple living with HIV or AIDS is higher than the preva-
lence of these disorders in HIV-negative controls.6 One 
meta-analysis suggests that the prevalence is at least 
double that in the general community.7 There is grow-
ing evidence that this is true in South Africa and other 
African countries.8-13 
The main factors contributing to the increased preva-
lence of depression and anxiety in individuals living 
with HIV are:
Biological, resulting from both direct and indirect 
forms of neurotoxicity due to HIV invasion of the 
central nervous system and the sequelae of immuno-
compromise. The areas predominantly affected are the 
sub-cortical areas of the brain, including those within 
the temporal lobes, which are the seat of emotional/
mental disorders.14 Depressive and anxiety disorders 
that occur as a result of HIV CNS infection often co-
exist with cognitive impairment that is also the result 
of this infection (see Box 1). Opportunistic conditions 
such as herpes simplex infection and various malig-
nancies, as well as certain medications used to treat 
these conditions and antiretroviral medications, can 
also cause depression or anxiety.15-16  
Psychological. The prevalence of depression and anxi-
ety in people living with HIV or AIDS is similar to that 
in people suffering from other serious, chronic and 
life-threatening medical illnesses.17 A major factor is 
the psychological reaction to having such an illness. 
The individual is faced with the reality of serious illness 
and possible death at an early age. In many cases there 
are additional stressors related to the stigma associ-
ated with HIV/AIDS and lack of social support for the 
infected individual (see Box 2).
Primary psychiatric disorder. Some individuals may be 
particularly vulnerable to depression and anxiety as a 
result of genetic loading or early childhood adversity.18 
Some HIV-infected individuals may already have a his-
tory of such mental disorder, or the stress of the illness 
(and the psychosocial consequences) may precipitate 
a depressive illness and/or an anxiety disorder. In ad-
dition, the time of first onset and presentation with 
primary psychiatric disorders is generally in young 
adulthood, and this is also the time when most people 
infected with HIV present for treatment or are diag-
nosed with the infection. Depressive or anxiety disor-
ders may be completely unrelated to HIV status, or the 
underlying mental disorder may have contributed to 
the events associated with acquiring HIV infection (e.g. 
alcohol abuse and sexual risk taking). 
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The term ‘common mental disorders’ is an overarching term for conditions that affect a significant number of 
people in the community. These conditions include depression, anxiety and substance use disorders. In contrast, 
so-called ‘severe mental illnesses’ (such as schizophrenia or bipolar mood disorder) are conditions that usually 
require admission for inpatient treatment and tend both to recur and to be chronically debilitating. Nonethe-
less, common mental disorders result in a considerable burden to the individual, their families, the community 
and the economy. Many people with these conditions do not present for treatment, or if they do they usually 
present to primary care facilities, where these diagnoses are often missed. This is unfortunate, since there is 
good evidence that these disorders can be effectively treated1-2 and that much of this treatment can be provided 
by primary care clinicians.3
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Several of the most frequently observed presentations 
of common mental disorders are listed in Table I. Iden-
tifying depression in a medically ill individual can be 
difficult owing to the overlap in somatic symptoms 
(e.g. loss of appetite or weight, sleep disturbance, pain, 
fatigue, poor concentration). It is important to consider 
mood and affect, particularly if alterations in these are 
constant, unvarying and more severe than is warranted 
by the individual’s circumstances, as well as anhedo-
nia (loss of pleasure in usually enjoyable activities) and 
functional impairment caused by the symptoms that 
are present. It is also suggested that an inclusive ap-
proach should be used when considering the criteria 
for making a diagnosis of depression in a medically ill 
individual.17 The relationship between substance abuse, 
mood and anxiety disorders and HIV infection is com-
plex, and all these disorders may play a role in increas-
ing the risk of being infected with HIV, as well as con-
tributing to the burden of disease, poor adherence and 
disease progression. 
Because the presentation of depression and anxiety can 
be unclear and because many people do not volunteer 
information about substance use disorder, it is criti-
cal that people who are infected with HIV should be 
screened for these disorders. A range of screening in-
struments have been validated in South Africa and are 
recommended for use.19-21 Some of these are self-re-
port instruments, while others are administered by the 
health worker. Once an individual is identified through 
screening, they should receive a more thorough assess-
ment by a trained clinician. 
The Substance Abuse and Mental Illness Symptoms 
Screener (SAMISS) is a 13-item screening question-
naire developed for use in HIV-positive individuals that 
can easily be applied in a busy primary care setting 
(Box 4). The SAMISS was found to have a sensitivity of 
86% and specificity of 95% in diagnosing DSM-IV-de-
fined substance use and depressive/anxiety disorders,22 
and validation of this tool in South Africa is underway. 
The advantages of using this instrument are that it is 
reasonably quick to administer and that it covers all 
the common mental disorders including substance use 
disorders. 
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ScreeninG For coMMon MenTal DiSorDerS in 
Hiv PriMarY care ServiceS
BoX 1
Mrs K is a 50-year-old woman living in a rural area. 
Her husband died of AIDS a year ago. She presents 
at the clinic with severe oral thrush. She is HIV posi-
tive and has severe weight loss. She looks depressed 
and is very tearful, complaining of fatigue and poor 
sleep and appetite. She has psychomotor retarda-
tion and her memory is poor. She is not on antiret-
roviral therapy. Her CD4 count is 150 cells/µl.
 
What possible diagnoses should you consider? How 
would you approach her treatment?
BoX 2
Mr M is a 29-year-old man who was recently di-
agnosed HIV positive when he presented to health 
services with a severe upper respiratory tract infec-
tion. His CD4 count is 250 cells/µl. He comes for 
a follow-up appointment in a dishevelled state, 
smelling of alcohol. He recently lost his job as a 
clerk in an office, his wife is unemployed and they 
have a young child. He starts crying in your office 
and voices suicidal ideation. 
What would your immediate management be? And 
in the longer term?
BoX 3
Ms B is a 24-year-old woman who was diagnosed 
HIV positive during antenatal screening. She had 
PMTCT and her baby was delivered safely 2 weeks 
ago. She is living with the father of the child, who is 
aware of her status and has also tested HIV positive. 
They are both currently asymptomatic. He is very 
supportive and it is their first child. She is extremely 
anxious about the well-being and HIV status of her 
baby. She complains that she is not sleeping and 
that she gets very irritable with the baby at times. 
Sometimes she finds herself just bursting into tears 
for no reason. 
What could be going on here? What are the risks in 
this situation? How would you manage her?
Presentation Features
Somatic   Headache, backache, abdominal pain - may be atypical, or show limited response to 
somatic treatments
Insomnia Common presentation; an important depressive symptom
Other neuro-vegetative symptoms Fatigue, weight loss, loss of energy and libido
Low mood or depression May be expressed differently, such as ‘stress’ or tension
Substance abuse  This commonly coexists with depression, and may be a presenting feature
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Substance use items:
1. How often do you have a drink containing alcohol? 
(Alcoholic drinks include one beer, one glass of wine, 
a mixed drink of hard liquor, or one wine cooler. Each of 
these counts as one drink, unless they have double shots, 
which would equal two drinks.) (If you do not drink, go 
to question 4.)
0 - Never 
1 - Monthly or less 
2 - 2 - 4 times a month  
3 - 2 - 3 times a week
4 - 4 or more times a week
2. How many drinks do you have on a typical day when 
you are drinking?
0 - 1 or 2 
1 - 3 or 4 
2 - 5 or 6
3 - 7 to 9
4 - 10 or more 
3. How often do you have four or more drinks on one 
occasion?
0 - Never 
1 - Monthly or less 
2 - 2 - 4 times a month
3 - 2 - 3 times a week
4 - 4 or more times a week
4. In the past year, how often did you use non-prescrip-
tion drugs to get high or change the way you feel?
0 -  Never 
1 - Monthly or less 
2 - 2 - 4 times a month
3 - 2 - 3 times a week
4 - 4 or more times a week
5. In the past year, how often did you use drugs pre-
scribed to you or to someone else to get high or change 
the way you feel?
0 - Never 
1 - Monthly or less 
2 - 2 - 4 times a month
3 - 2 - 3 times a week
4 - 4 or more times a week
6. In the last year, how often did you drink or use drugs 
more than you meant to?
0 - Never 
1 - Monthly or less 
2 - 2 - 4 times a month
3 - 2 - 3 times a week
4 - 4 or more times a week
7. How often did you feel you wanted or needed to cut 
down on your drinking or drug use in the last year, and 
not been able to?
0 - Never 
1 - Monthly or less 
2 - 2 - 4 times a month
3 - 2 - 3 times a week
4 - 4 or more times a week
Patient considered positive for substance use symptoms 
if any of the following criteria are met:
a) The sum of responses for questions 1 - 3 is >5  
b) The sum of responses for questions 4 - 5 is >3
c) The sum of responses for questions 6 - 7 is >1
Mental health items:
Medications/antidepressants
8. During the past 12 months, were you ever on medica-




9. During the past 12 months, was there ever a time 
when you felt sad, blue or depressed for 2 weeks or more 
in a row?
1 - Yes
2  - No
10. During the past 12 months, was there ever a time 
lasting 2 weeks or more when you lost interest in most 





11. During the past 12 months, did you ever have a pe-
riod lasting 1 month or longer when most of the time 




12. During the past 12 months, did you have a spell 
or an attack when all of a sudden you felt frightened, 




13. During the past 12 months, did you ever have a spell 
or an attack when for no reason your heart suddenly 
started to race, you felt faint, or you couldn’t catch your 
breath? [If respondent volunteers ‘only when having a 
heart attack or due to physical causes’, mark ‘No’.]
1 - Yes
2 - No
Patient considered positive for symptoms of mental ill-
ness if he/she responded yes to any mental health ques-
tion.
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Given the increased risk of common mental disorders 
in HIV-infected individuals, it makes sense to put basic 
preventive services into place in HIV treatment serv-
ices. These include support groups, counselling, psy-
cho-education, social work and occupational therapy 
interventions, as available. It is important to note that 
services of this kind are commonly available as part 
of HIV primary care services (particularly in the con-
text of antiretroviral therapy), but are usually focused 
on treatment initiation and adherence; however, such 
types of psychosocial support have important addi-
tional benefits in promoting mental health. Individuals 
who provide this kind of psychosocial support should 
be trained to identify patients who may have a com-
mon mental disorder (e.g. using the SAMISS), and to 
refer them for appropriate assessment and interven-
tion. Ideally, psychiatric and mental health care services 
should be offered on site in HIV treatment services, but 
this may not always be possible and specialist services 
are not required to effectively diagnose and manage 
many common mental disorders. Alternatively, it would 
be important to identify referral resources and estab-
lish good links and communication channels between 
the HIV treatment service and the psychiatric/mental 
health services. 
Treating common mental disorders has direct benefits 
on the quality of life and well-being of affected indi-
viduals. In addition, there is evidence from internation-
al research that untreated depressive and anxiety dis-
orders lead to poor antiretroviral adherence23 and may 
speed HIV disease progression.24-26 The management of 
mental disorders requires a holistic approach with at-
tention to biological as well as psychosocial factors. 
BioloGical ManaGeMenT
identify and treat any underlying or associated 
general medical condition
HIV infection itself is associated with features of de-
pression and apathy. Other chronic conditions such as 
peripheral neuropathy, or intra-cranial secondary in-
fections or tumours, may produce depression. These 
include progressive multifocal leuco-encephalopathy 
or vasculopathy. Usually a careful history, physical ex-
amination and routine investigations (e.g. serological 
testing for syphilis) are adequate to rule these out as 
causes of psychiatric symptoms, and special investiga-
tions (such as lumbar puncture or computed tomog-
raphy of the brain) are not necessary in many primary 
care settings. 
assess cognitive impairment
Cognitive impairment often co-exists with depressive 
disorders, and may be a confounding variable. It is 
sometimes difficult to assess whether there is depres-
sion in the presence of dementia, and depressive illness 
may also present with cognitive features consistent 
with dementia. If there are other features and mark-
ers of late-stage HIV infection, the need for antiret-
roviral medication should be considered, as this is an 
important treatment for HIV-associated dementia (see 
related article by Singh in this edition).  
assess for suicidality
Suicidal ideation is common in HIV-infected individu-
als. In a study in South Africa,27 22.5% of a sample 
of HIV-infected individuals attending HIV treatment 
sites had experienced suicidal ideation in the past, and 
8.6% had current suicidal ideation; 69% of the par-
ticipants with past suicidal ideation had experienced 
this as a result of their diagnosis. The period after di-
agnosis is therefore a period of high risk. In the same 
study, suicidal ideation was strongly associated with 
the presence of a depressive disorder. It is important 
to ask patients who are at high risk about thoughts of 
suicide, as these may not be volunteered. A thorough 
risk assessment should be conducted, and the need for 
inpatient admission should always be considered. 
Treat depressive or anxiety disorders with medication 
when necessary
Antidepressant medication is effective in treating both 
depressive and anxiety disorders in HIV-infected peo-
ple, even in the presence of cognitive impairment (for 
more detail on specific medications and their use, see 
the article in this edition on psychotropic prescribing 
in HIV-infected individuals). Antidepressant medi-
cation can be used safely in combination with anti- 
retroviral medication, as long as one is aware of sever-
al specific drug interactions and monitors the patient, 
adjusting medication when necessary.  Generally anti-
depressant medication should be used for 6 months to 
1 year to treat a single episode of a depressive illness. 
People with recurrent episodes should remain on long-
term treatment. Anxiety disorders are best managed 
with a combination of psychosocial interventions and 
judicious use of medication. Benzodiazepines should 
be avoided, only being used in acute crisis situations 
for short periods of time (less than 2 weeks). Should 
medication be needed to manage anxiety, the selective 
serotonin reuptake inhibitors (SSRIs) should be used. 
Manage substance withdrawal and provide 
rehabilitation for substance use disorders
The initial intervention in terms of substance use disor-
ders is safe medical detoxification, followed by assess-
PrevenTion oF coMMon MenTal DiSorDerS in 
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ment of the need for and possibilities of rehabilitation. 
Motivational interviewing is a useful tool for engaging 
people with substance use disorders in treatment of 
their addictive behaviour. Rehabilitation usually con-
sists of group and individual psychotherapy, and can 
usually be managed on an outpatient basis. Support 




There is evidence of benefit from interpersonal psy-
chotherapy for the treatment of depressive disorders in 
HIV-infected individuals.28 Cognitive-behavioural ther-
apy (CBT) has been shown to have benefit in depressive 
illnesses in general primary health care.28 Supportive 
therapy and support groups are not sufficient where 
individuals are depressed, but support group facilita-
tors should be trained to identify people who may be 
depressed. An adaptation of CBT for people living with 
HIV, called cognitive-behavioural stress management 
(CBSM), has been found to be effective when conduct-
ed in group settings in HIV clinics in the USA.28 This 
intervention includes didactics on physiological effects 
of stress, stress management strategies, CBT interpre-
tation of stress and emotions (addressing cognitive 
distortions, automatic thoughts), coping skills training, 
assertiveness training, anger management, identifica-
tion of social supports, and group support. This is a 
structured intervention that could be implemented in 
HIV clinics or primary care settings where group treat-
ment can be used to treat a number of depressed indi-
viduals at the same time, and it deserves attention in 
South Africa. 
 
Most common mental disorders can be managed ef-
fectively in primary care, but there are several specific 
indications for referring a patient to specialist psychi-
atric and mental health services (Box 5). 
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Indications for referring a patient to specialist psy-
chiatric and mental health services:
1.    Any patient who requires inpatient treatment 
should be referred for a psychiatric assessment.
2.    Any patient who presents with suicidal ideation 
should be referred for a psychiatric assessment.
3.    Failure to respond to primary care interventions 
as outlined above. 
4.    Patients who fail to respond to an equivalent 
dose of fluoxetine or citalopram of 20 mg per 
day for a depressive or anxiety disorder should 
be referred for a psychiatric assessment or 
opinion.
Mrs K (Box 1) has stage 3 or 4 HIV disease. She 
may have neurocognitive impairment and she may 
also have a depressive disorder. Assessment should 
include physical examination, and assessment of 
her cognitive status. She is clearly a candidate for 
antiretroviral therapy, which should be started as 
soon as possible. One would re-assess her mental 
state regularly, and if her mood did not lift once she 
has recovered physically, one would consider start-
ing her on an SSRI.
A suicide risk assessment should be carried out on 
Mr M (Box 2). Because he is intoxicated, he would 
need to be supervised until he became sober. His 
wife could be called into the clinic to discuss the 
situation with her. It would be important to educate 
him about alcohol abuse and its consequences in 
terms of his HIV status as well as his mood. An-
other important consideration would be when to 
start antiretroviral treatment. A social work referral 
should be made for assistance or advice regarding 
the couple’s financial situation, as well as referral 
to a support group or a psychologist depending on 
his condition. His mood should be monitored over 
time and if it remains low one would consider start-
ing him on an antidepressant. 
Ms B (Box 3) could be suffering from postpartum 
depression. It is important to assess her mental 
state and do a risk assessment with regard to self-
harm as well as possible harm to her baby. One 
could call her husband in and discuss the situation 
with them both. If she has features of a depressive 
disorder, she should be started on an SSRI. It is also 
important to make sure that there is adequate sup-
port and supervision for her and her baby. If the 
safety of either is a concern, she should be admitted 
to hospital. 
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